PapersPMID:41006034
Antitumor Potential of Epigallocatechin Gallate in Overcoming Molecular Therapy Resistance in Hepatocellular Carcinoma.
What moved
1 findingHow to read these marks →- Inhibits EGFR
insufficient
“EGCG also suppressed EGFR expression, especially in Hep3BLR.”
- Study
- in vitro · not in humans
- Dose studied
- 10 μg/ml
- Population
- Hep3B human hepatocellular carcinoma cells and the lenvatinib-resistant Hep3BLR subline
Study record
- Design
- in vitro
- Species
- mixed
- Population
- Hep3B human hepatocellular carcinoma cells, lenvatinib-resistant (Hep3BLR) and sorafenib-resistant (Hep3BSR) sublines; nude mouse xenografts used for miR-575 mimic functional validation (not EGCG dosing)
- Participants
- not reported
- Comparator
- not stated in the paper
- Duration
- not reported
- Endpoints measured
- 5
(-)-epigallocatechin 3-gallate